Top 10 Neurodegenerative Diseases Companies in APAC - 2023
Neurodegenerative diseases like Alzheimer’s disease, Friedreich ataxia, Amyotrophic lateral sclerosis, and Parkinson's disease are at an all-time high, and so is the awareness about these diseases. This has propelled the market for neurodegenerative diseases and has given rise to a strong pipeline of treatments for such conditions.
According to research, the global neurodegenerative diseases market was valued at USD 40,125 million at the end of the last decade and is estimated to reach USD 53,275 million by 2030 at an astounding cumulative annual growth rate (CAGR) of 3.20 per cent. Out of this, the APAC market itself is predicted to be worth USD 13,530 million by 2030 recording a massive 5.03 per cent CAGR.
This Life Sciences Review issue highlights some of the most significant developments in the APAC market for neurodegenerative diseases and the considerable expansion of the sector in recent years. It features TauRx, founded to address one of the world's most pressing unmet medical needs - Alzheimer's disease and other neurodegenerative disorders - by targeting misfolding and aggregation of tau proteins. Its mission is to discover, develop, and commercialize novel products to diagnose, treat, and cure neurodegenerative diseases caused by protein aggregation.
The magazine also includes the insightful viewpoints of Steven Henck, PhD, Vice President of R&D, Integrated DNA Technologies, and Claus Feussner, Senior Vice President of Vetter Development Service, Vetter Pharma. They each address several valuable points related to treating Neurodegenerative diseases in the current technologydriven world.
Write to us about how the advancements in the APAC region's neurodegenerative diseases market have affected your organisation's functioning!




